Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as the primary mechanism of vaccine-induced protection against HIV-1
Preprint
Abstract
A gene signature previously correlated with mosaic adenovirus 26 vaccine protection in simian immunodeficiency virus (SIV) and SHIV challenge models in non-human primates (NHP). In this report we investigated presence of this signature as a correlate of reduced risk in human clinical trials and potential mechanism for protection. The absence of this gene signature in the DNA/rAd5 human vaccine trial which did not show efficacy, strengthens our hypothesis that this signature is only enriched in studies that demonstrated protection. This gene signature was enriched in the partially effective RV144 human trial that administered the ALVAC/protein vaccine, and we find that the signature associates with both decreased risk of HIV-1 acquisition and increased vaccine efficacy. Total RNA-seq in a clinical trial that used the same vaccine regimen as the RV144 HIV vaccine implicated antibody-dependent cellular phagocytosis (ADCP) as a potential mechanism of vaccine protection. CITE-seq profiling of 53 surface markers and transcriptomes of 53,777 single cells from the same trial, showed that genes in this signature were primarily expressed in cells belonging to the myeloid lineage including monocytes, which are major effector cells for ADCP. The consistent association of this transcriptome signature with vaccine efficacy represents a tool both to identify potential mechanisms, as with ADCP here, and to screen novel approaches to accelerate development of new vaccine candidates.Keywords
All Related Versions
- Published version: eLife, 10.
This publication has 43 references indexed in Scilit:
- Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyThe Lancet HIV, 2020
- Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIVNature Medicine, 2018
- Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)The Lancet, 2018
- Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challengeNature Communications, 2017
- Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeysScience, 2015
- Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus MonkeysCell, 2013
- A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samplesJournal of Immunological Methods, 2011
- Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income CountriesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- WEIGHTED LIKELIHOOD, PSEUDO-LIKELIHOOD AND MAXIMUM LIKELIHOOD METHODS FOR LOGISTIC REGRESSION ANALYSIS OF TWO-STAGE DATAStatistics in Medicine, 1997
- Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infectionProceedings Of The Royal Society B-Biological Sciences, 1995